Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-Polycythemia Vera
Post-Essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Momelotinib

Sponsor

Sierra Oncology LLC - a GSK company